Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changchun
Clinical trial register · China

Clinical Trials in Changchun, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 5582 Shanghai 3880 Guangzhou 3354 Hangzhou 1824 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca105 The First Hospital of Jilin University49 Hoffmann-La Roche31 Janssen Research & Development, LLC30 Eli Lilly and Company25
Site location
Beijing5582 Shanghai3880 Guangzhou3354 Hangzhou1824 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Changchun

640 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Shanghai HEP Pharmaceutical Co., Ltd.
Phase 3
150
Changchun
2027-06
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2027-01-11
Not yet open
Eli Lilly and Company
Phase 3
2,115
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan
2026-12
Not yet open
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
270
Fuzhou, Harbin, Changsha, Nanchang, Changchun, Shanghai, Taizhou
2026-11-01
Not yet open
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
DrugMazdutide
Tongji Hospital
Phase 2
128
Zhengzhou, Wuhan, Changchun, Hangzhou, Shanghai, Tianjin
2026-11-01
Recruiting
The First Hospital of Jilin University
Phase 3
148
Changchun
2026-10-28
Not yet open
SPH Sine Pharmaceutical Laboratories Co., Ltd.
Phase 2
150
Beijing, Chongqing, Shenzhen, Liuzhou, Xinxiang, Shiyan, Zhuzhou, Changchun
2026-10-20
Recruiting
Eli Lilly and Company
Phase 3
1,000
Changchun, Jinan, Luoyang Shi, Nanjing, Ningbo, Shijiazhuang, Tianjin
2026-10-16
Recruiting
The First Hospital of Jilin University
Phase 4
26
Changchun
2026-10-15
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsDS-1103a·DS-3939a·Pemetrexed·Carboplatin
Daiichi Sankyo
Phase 1/2
400
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Hexi District, Tianjin, Jiamusi
2026-10-13
Not yet open
Nutritional Intervention for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT07850375Hematopoietic Stem Cell Transplantation (HSCT), Malnutrition (Calorie)
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
160
Changchun, Tianjin, Wenzhou
2026-10-12
Recruiting
AstraZeneca
Phase 3
140
Beijing, Bengbu, Changchun, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2026-10-09
Recruiting
Hoffmann-La Roche
Phase 3
400
Hefei, Shenzhen, Jinan, Chengdu, Hangzhou, Beijing, Changchun, Foshan
2026-10-06
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Guangzhou, Shijiazhuang, Changchun, Xianyang, Beijing, Fuzhou, Hangzhou, Nanchang
2026-10-02
Not yet open
Mundipharma (China) Pharmaceutical Co. Ltd
Observational
378
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2026-10
Recruiting
AstraZeneca
Observational
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2026-09-28
Recruiting
HMPL-A830 in Solid Tumors
NCT07718581Solid Tumor, Adult
Hutchmed
Phase 1/2
147
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Jinan, Nanjing, Taiyuan
2026-09-24
Not yet open
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Not yet open
Treatment Strategy for Patients With RA-ILD
NCT07643038Rheumatoid Arthritis Associated Interstitial Lung Disease
DrugsTocilizumab·Methotrexate·Rituximab
Chinese SLE Treatment And Research Group
Phase 4
204
Luoyang, Beijing, Changchun, Chongqing, Dalian, Handan, Hangzhou, Hefei
2026-09-20
Recruiting
4D Molecular Therapeutics
Phase 3
514
Beijing, Changchun, Changsha, Haerbin, Hangzhou, Jinan, Lanzhou, Nanchang
2026-09-18
Recruiting
AstraZeneca
Phase 3
286
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2026-09-17
Recruiting
AstraZeneca
Phase 3
950
Anyang, Beijing, Binzhou Shi, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2026-09-16
Recruiting
Jiangsu Jingze Biopharmaceutical Co., Ltd.
Phase 2
48
Hefei, Beijing, Lanzhou, Shenzhen, Nanning, Shijiazhuang, Wuhan, Changchun
2026-09-08
Recruiting
AstraZeneca
Phase 3
2,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2026-09-01
Recruiting
Vision-Language-Based Large-Scale Model for Emergency Screening
NCT07899931Acute Thoraco-Abdominal Emergency Lesions
The First Hospital of Jilin University
Not applicable
640
Changchun
2026-09-01
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
36
Changchun
2026-09
Not yet open
Shanghai Simnova Biotechnology Co.,Ltd.
Early Phase 1
28
Changchun
2026-09
Recruiting
AstraZeneca
Phase 3
417
Beijing, Bengbu, Changchun, Changde, Changlexi, Changsha, Chengdu, Dalian
2026-08-31
Recruiting
AstraZeneca
Phase 3
500
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
2026-08-24
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Baoding, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,500
Beijing, Cangzhou, Changchun, Chengdu, Danyang, Ganzhou, Guangzhou, Huizhou
2026-08-20
Recruiting
Safety and Short-term Outcomes of Modular Robotic System for Siewert II/III Gastroesophageal Junction Cancer
NCT07790809Siewert Type II/III Gastroesophageal Junction Adenocarcinoma
The First Hospital of Jilin University
Not applicable
25
Changchun
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang
2026-08-19
Recruiting
Parr Biotechnology (Hebei) Co., Ltd.
Phase 1
44
Changchun
2026-08-17
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
42
Beijing, Xinxiang, Nanjing, Nanchang, Changchun, Jinan, Taiyuan, Tianjin
2026-08-15
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Changchun, Chengdu, Chongqing, Fuzhou, Ha’erbin, Jinan, Kunming, Luoyang
2026-08-13
Not yet open
Total Arterial vs. Mixed Grafting in Left Coronary CABG
NCT07057713Coronary Artery Disease, Coronary Artery Bypass Grafting, Arterial Graft, Graft Patency
Second Hospital of Jilin University
Not applicable
400
Changchun
2026-08-01
Not yet open
Evaluation of NWRD09 for HPV-16 Related Cervical HSIL
NCT07712692High-grade Squamous Intraepithelial Lesion (HSIL)
DrugNWRD09
Newish Biotech (Wuxi) Co., Ltd.
Phase 2
156
Beijing, Chongqing, Lanzhou, Baoding, Zhengzhou, Nanjing, Changchun, Jinan
2026-08-01
Not yet open
Laekna Limited
Phase 1
150
Hefei, Beijing, Changchun, Shanghai, Hangzhou
2026-08
Not yet open
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
NCT07708285NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma
DrugsLuvometinib·Serplulimab
Beijing Tiantan Hospital
Phase 1/2
30
Beijing, Changchun, Shanghai
2026-07-31
Not yet open
Chongqing Jinsaixing Medical Technology Co., Ltd
Observational
570
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Changchun, Shanghai, Chengdu
2026-07-31
Active, closed
The First Hospital of Jilin University
Phase 2
62
Changchun
2026-07-30
Recruiting
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
20
Beijing, Changchun, Fuzhou, Jinan, Shanghai, Shijiazhuang, Taiyuan, Tianjin
2026-07-27
Not yet open
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
NCT07713745Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma
DrugsLuvometinib·Selumetinib·Serplulimab
Beijing Tiantan Hospital
Phase 2
200
Beijing, Changchun, Shanghai
2026-07-18
Recruiting
Boehringer Ingelheim
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2026-07-10
By invitation
The First Hospital of Jilin University
Observational
100
Changchun
2026-07-04
Recruiting
Hoffmann-La Roche
Phase 3
300
Zhengzhou, Xianyang, Ningbo, Beijing, Changchun, Hefei, Herbin, Huai'an
2026-07-03
Recruiting
manxiaxia
Not applicable
52
Changchun
2026-07-01
Not yet open
Second Hospital of Jilin University
Observational
150
Changchun
2026-07-01
Recruiting
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
NCT07719140Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
DrugPrednisone
Peking Union Medical College Hospital
Phase 4
198
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Changchun, Shanghai
2026-07
Not yet open
Chengdu Suncadia Medicine Co., Ltd.
Phase 1
74
Changchun
2026-07
Recruiting
Genmab
Phase 3
82
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan
2026-06-26
Recruiting
Immune Mechanisms and ECMO Strategies for Moderate-to-Severe ARDS
NCT07726940Acute Respiratory Distress Syndrome (ARDS)
Southeast University, China
Observational
1,776
Beijing, Fuzhou, Nanjing, Jinan, Chengdu, Hangzhou, Changchun, Chenzhou
2026-06-16
Recruiting
Full-Course ECMO Strategy for Moderate-to-Severe ARDS
NCT07726953Acute Respiratory Distress Syndrome
Southeast University, China
Not applicable
500
Beijing, Changchun, Chengdu, Chenzhou, Dalian, Fuzhou, Guangzhou, Hangzhou
2026-06-16
Not yet open
Ou Bai, MD/PHD
Phase 2
66
Changchun
2026-06-16
Not yet open
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
NCT07699770Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
DrugCrisugabalin
Tang-Du Hospital
Phase 4
110
Beijing, Chongqing, Harbin, Hohhot, Changchun, Shenyang, Xi'an, Ürümqi
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing
2026-06-11
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1
48
Changchun
2026-06-09
Recruiting
Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms
NCT07612748Rectal Neuroendocrine Tumors, ESD, EPMR
Jilin University
Not applicable
483
Changchun
2026-06-01
Not yet open
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
NCT07550634Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
DrugMDR-001
MindRank AI Ltd
Phase 1
32
Changchun
2026-06-01
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
144
Beijing, Changchun, Changsha, Hangzhou, Kunming, Nanjing, Nanning, Qingdao
2026-05-31
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing
2026-05-31
Recruiting
Ou Bai, MD/PHD
Phase 3
200
Changchun
2026-05-30
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang, Changchun, Jinan
2026-05-27
Recruiting
AbbVie
Phase 3
990
Beijing, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Wuxi, Changchun
2026-05-22
Recruiting
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis
NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Changchun, Jinan
2026-05-15
Not yet open
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
Ipsen
Phase 3
350
Beijing, Guangzhou, Zhengzhou, Nanchang, Changchun, Jinan, Shanghai, Tianjin
2026-05-14
Recruiting
Jilin University
Not applicable
36
Changchun, Ch’ang-ch’un
2026-05-12
Recruiting
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
NCT07316270AF - Atrial Fibrillation, Intracranial Hemorrhage, Spontaneous
Beijing Anzhen Hospital
Not applicable
646
Hefei, Beijing, Xiamen, Harbin, Changchun, Xi'an
2026-05-06
Not yet open
MindRank AI Ltd
Phase 1
28
Changchun
2026-05-06
Active, closed
The First Hospital of Jilin University
Phase 4
40
Changchun
2026-05-01
Not yet open
China-Japan Union Hospital
Not applicable
220
Changchun
2026-05-01
Not yet open
Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
NCT06981390Coronary Artery Disease, Coronary Artery Bypass Grafting, Saphenous Vein, Dual Antiplatelet Therapy
DrugTicagrelor
Kexiang Liu, MD
Not applicable
300
Changchun
2026-05-01
Recruiting
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Not yet open
The First Hospital of Jilin University
Observational
1,424
Changchun
2026-04-30
Recruiting
Ou Bai, MD/PHD
Phase 2
50
Changchun
2026-04-30
Recruiting
Huahui Health
Phase 3
160
Changchun, Kashgar, Ürümqi
2026-04-22
Recruiting
Boehringer Ingelheim
Phase 2
405
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai
2026-04-20
Not yet open
GS1-144 in Participants With Hepatic Impairment and Healthy Female
NCT07491289Hepatic Impairment and Healthy Female
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
24
Changchun
2026-04-20
Recruiting
The First Hospital of Jilin University
Phase 2
220
Changchun
2026-04-10
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
370
Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai
2026-04-07
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Recruiting
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Not yet open
Ou Bai, MD/PHD
Observational
40
Changchun
2026-04-01
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Baotou, Nanjing, Suzhou, Changchun
2026-04-01
Recruiting
Eisai Inc.
Phase 2
64
Beijing, Changchun, Guangdong, Guangzhou, Jinan, Nanchang, Shanghai, Zhengzhou
2026-03-26
Recruiting
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Active, closed
AstraZeneca
Observational
146
Guangzhou, Shenyang, Jinan, Changchun, Changsha, Chengdu, Haikou, Kunming
2026-03-19
Recruiting
Tamsulosin for Early Catheter Removal After Rectal Cancer Surgery
NCT07346586Urinary Catheters, Rectal Cancer, Urinary Retention
The First Hospital of Jilin University
Not applicable
1,545
Harbin, Changchun
2026-03-18
Recruiting
The First Hospital of Jilin University
Not applicable
520
Changchun
2026-03-18
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Zhenjiang, Xianyang, Jinan, Beijing, Changchun, Hefei, Herbin, Huizhou
2026-03-16
Not yet open
Yi Yang
Not applicable
530
Changchun
2026-03-15
Recruiting
Hutchmed
Phase 1/2
186
Changchun, Changsha, Jinan, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
2026-03-04
By invitation
Northeast Normal University
Not applicable
48
Changchun
2026-03-01
Recruiting
Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
NCT07846462Coronary Artery Disease, Acute Coronary Syndromes, Chronic Coronary Syndrome, Percutaneous Coronary Intervention
DrugsTicagrelor·Clopidogrel·Aspirin
Jilin University
Not applicable
2,640
Changchun
2026-03-01
Recruiting
Beijing Anzhen Hospital
Not applicable
564
Beijing, Changchun, Dalian, Nanchang, Shanghai
2026-02-25
Recruiting
The First Hospital of Jilin University
Phase 2/3
212
Changchun
2026-02-23
Recruiting
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Recruiting
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
By invitation
Innovative Probe With Laser on Radial Artery Puncture and Catheterisation in Paediatric
NCT07454005Radial Artery Catheterization, Paediatric, Ultrasound Guided
The First Hospital of Jilin University
Not applicable
408
Changchun
2026-02-11
Recruiting
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Not yet open
MindRank AI Ltd
Phase 3
738
Beijing, Changchun, Changde, Changsha, Datong, Dongyang, Ganzhou, Hefei
2026-02
Not yet open
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 4
60
Changchun
2026-01-30
Recruiting
Genmab
Phase 2
240
Shanghai, Beijing, Changchun, Nanjing, Tianjin, Zhangjiakou, Zhengzhou
2026-01-30
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Recruiting
Hoffmann-La Roche
Observational
500
Xiamen, Lanzhou, Shijiazhuang, Changchun, Wenzhou, Beijing, Chengdu, Chongqing
2026-01-21
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Recruiting
Zan Wang
Not applicable
404
Changchun
2026-01-20
Recruiting
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
Bristol-Myers Squibb
Observational
500
Beijing, Guangzhou, Jiazhuang, Zhengzhou, Suzhou, Changchun, Dalian, Xi'an
2026-01-15
Recruiting
Novo Nordisk A/S
Phase 3
460
Beijing, Zhengzhou, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2026-01-08
Recruiting
Impact of Stepwise Pressure-Increasing NC Balloon Post-Dilation on Stent Expansion
NCT07853261Coronary Artery Disease, Drug Eluting Stents
Jilin University
Not applicable
150
Changchun
2026-01-07
Recruiting
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
NCT07303803MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
DrugsChiglitazar·Vitamin E
Shanghai Jiao Tong University School of Medicine
Phase 2
300
Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Shiyan, Changsha, Changchun
2026-01-01
Not yet open
Beijing Children's Hospital
Not applicable
2,650
Beijing, Chongqing, Guangzhou, Baoding, Zhengzhou, Wuxi, Changchun, Xi'an
2026-01-01
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
NCT07509086Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL)
The First Hospital of Jilin University
Phase 2
25
Changchun
2025-12-29
Recruiting
Tongji Hospital
Phase 2
77
Xiamen, Wuhan, Changchun, Taiyuan
2025-12-25
Recruiting
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou Fujian
2025-12-22
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
92
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun
2025-12-16
Recruiting
AstraZeneca
Phase 2
320
Beijing, Changchun, Changsha, Guangzhou, Jiujiang, Kunming, Linyi, Nanchong
2025-12-15
Not yet open
Chunyan Ma
Observational
1,740
Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
BioNTech SE
Phase 2
105
Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming
2025-12-04
Recruiting
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
Active, closed
UCB Biopharma SRL
Phase 4
40
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen
2025-12-01
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Not yet open
First Hospital of China Medical University
Observational
2,640
Chongqing, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xiangyang, Changchun
2025-12
Recruiting
SA1211 Injection Phase 1 Study
NCT07275918Chronic Hepatitis B
Suzhou Siran Biotechnology Co.,Ltd.
Phase 1
80
Changchun
2025-11-25
Recruiting
Shanghai Henlius Biotech
Phase 1
246
Beijing, Bengbu, Changchun, Changsha, Chengdu, Dongguan, Fuzhou, Ganzhou
2025-11-25
By invitation
Northeast Normal University
Not applicable
90
Changchun
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
By invitation
Northeast Normal University
Not applicable
90
Changchun
2025-11-20
Recruiting
Ruijin Hospital
Phase 2
35
Sanming, Changchun, Shanghai
2025-11-17
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
400
Changchun, Tianjin, Hangzhou
2025-11-15
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zunyi, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Haikou
2025-11-11
Recruiting
tongweihua
Phase 3
60
Changchun
2025-11-10
Recruiting
The First Hospital of Jilin University
Phase 2
30
Changchun
2025-11-01
Recruiting
The First Hospital of Jilin University
Not applicable
98
Changchun
2025-11-01
Not yet open
RATME Vs LATME in Middle and Low Rectal Cancer
NCT06105203Total Mesorectal Excision, Rectal Neoplasms, Robotic Surgical Procedures, Laparoscopy
The First Hospital of Jilin University
Not applicable
1,026
Changchun
2025-11-01
Recruiting
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1
12
Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
2025-10-29
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
Distribution Characteristics of Helicobacter Pylori
NCT07253948Helicobacter Pylori, Early Gastric Cancer
Jilin University
Observational
231
Changchun
2025-10-22
Recruiting
GlaxoSmithKline
Phase 3
1,196
Shapingba, Nanning, Chengdu, Suining, Beijing, Changchun, Changsha, Chongqing
2025-10-20
Recruiting
Association of Biomarkers and Gastric Antral Motility Index With Feeding Intolerance in Critically Ill Patients
NCT07178626Critically Ill Patients Who Are Not Allowed to Eat Orally But Can Initiate Enteral Nutrition Within 48 Hours of ICU
The First Hospital of Jilin University
Observational
160
Changchun
2025-10-20
Not yet open
The First Hospital of Jilin University
Phase 1
30
Changchun
2025-10-15
Active, closed
Fertility Decision and Outcomes in Young Women With Breast Cancer
NCT07804745Breast Cancer - Female, Fertility
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
300
Changchun, Hangzhou
2025-10-15
Recruiting
Shanghai QuietD Biotechnology Co., Ltd.
Phase 2
120
Meizhou, Luoyang, Nanyang, Changchun, Meihekou, Benxi, Fuxin, Shengyang
2025-10-14
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Not yet open
Yi Yang
Not applicable
102,072
Changchun
2025-10
Recruiting
Daiichi Sankyo
Phase 3
710
Beijing, Changchun, Chengdu, Hangzhou, Jinan, Linyi, Nanchang, Nanning
2025-09-30
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Baotou, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Dongguan
2025-09-30
Recruiting
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Bengbu, Beijing, Guangzhou, Luoyang, Pingxiang, Changchun, Ürümqi, Kunming
2025-09-26
Recruiting
BioNTech SE
Phase 1/2
880
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2025-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,101
Xuzhou, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-09-17
Recruiting
Sanofi
Phase 3
942
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian
2025-09-17
Recruiting
Sanofi
Phase 3
942
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin
2025-09-16
Recruiting
Candid Therapeutics
Phase 1
44
Fuzhou, Guangzhou, Guiyang, Zhengzhou, Changchun, Shanghai, Taiyuan, Chengdu
2025-09-16
Not yet open
Risk-adapted Therapeutic Strategy in +1q NDMM
NCT07045168Multiple Myeloma
FengYan Jin
Observational
200
Changchun
2025-09-15
Recruiting
The PRE-VAIL Study
NCT07176624ARDS (Moderate or Severe), Prone Position, Enteral Nutrition Feeding, Intensive Care Unit (ICU) Admission
The First Hospital of Jilin University
Not applicable
259
Changchun
2025-09-14
Recruiting
The Effect of the Timing of Supplemental Parenteral Nutrition on the Prognosis of Critically Ill Patients (T-SPN)
NCT07085455Critical Illness, Organ Dysfunction, Enteral Nutrition Intolerance, Inadequate Nutritional Intake
Dong Zhang
Not applicable
946
Changchun
2025-09-09
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Beijing, Binhai, Changchun, Changsha, Chengdu, Chenzhou, Chifeng, Chongqing
2025-09-06
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
280
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan
2025-09-05
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2025-09-02
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong
2025-09-02
Recruiting
Nefecon and Ambrisentan in IgA Nephropathy
NCT07030894IgA Nephropathy, Chronic Kidney Disease, Proteinuria
The First Hospital of Jilin University
Phase 4
129
Changchun
2025-09-01
Not yet open
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 2/3
268
Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun
2025-08-31
Recruiting
The First Hospital of Jilin University
Not applicable
380
Changchun
2025-08-31
Recruiting
Biotheus Inc.
Phase 2
100
Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2025-08-19
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
159
Beijing, Fuzhou, Guangzhou, Changchun, Shanghai
2025-08-15
Recruiting
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Recruiting
AstraZeneca
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-08-01
Not yet open
Liu Hongfang
Not applicable
228
Beijing, Guangzhou, Changchun, Tianjin
2025-08-01
Not yet open
Liu Hongfang
Observational
4,472
Beijing, Guangzhou, Changchun, Tianjin
2025-08-01
Not yet open
Shanghai Zhimeng Biopharma, Inc.
Phase 3
1,300
Changchun
2025-08
Recruiting
Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions
NCT07439965Subarachnoid Aneurysm Hemorrhage, Unruptured Intracranial Aneurysm
The First Hospital of Jilin University
Observational
120
Changchun
2025-07-29
Recruiting
AbbVie
Phase 3
120
Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou
2025-07-28
Recruiting
The First Hospital of Jilin University
Phase 4
115
Changchun
2025-07-24
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
Daiichi Sankyo
Phase 2
130
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao
2025-07-18
Recruiting
AstraZeneca
Phase 2
100
Beijing, Changchun, Changzhi, Chengdu, Fuzhou, Hangzhou, Kunming, Qingdao
2025-07-17
Active, closed
Aligos Therapeutics
Phase 2
200
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai
2025-07-15
Recruiting
Smith & Nephew, Inc.
Not applicable
105
Guangzhou, Zhengzhou, Nanjing, Changchun, Hangzhou
2025-07-02
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing
2025-07-02
Recruiting
Yehui Tan
Phase 2
46
Changchun
2025-07-01
Recruiting
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Not yet open
PD-1-M1-NK Cells in the Treatment of Advanced Gastric or Colorectal Cancer
NCT07031011Advanced Gastric or Colorectal Cancer
jiuwei cui
Phase 1
22
Changchun
2025-06-30
Not yet open
Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO
NCT07042490Acute Ischemic Stroke From Large Vessel Occlusion, Endovascular Thrombectomy
Yi Yang
Not applicable
100
Changchun
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Recruiting
A Phase I Study of HW201877 in Healthy Subjects
NCT07373457Healthy Participants, IBD (Inflammatory Bowel Disease)
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1
104
Changchun
2025-06-26
Recruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Phase 1
28
Changchun
2025-06-26
Active, closed
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Recruiting
GlaxoSmithKline
Phase 3
981
Haikou, Changsha, Chengdu, Beijing, Changchun, Chongqing, Dongguan, Fuyang
2025-06-20
Recruiting
Pfizer
Phase 2
620
Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an
2025-06-19
Recruiting
China-Japan Union Hospital
Phase 4
200
Changchun
2025-06-16
Not yet open
The First Hospital of Jilin University
Phase 2
30
Changchun
2025-06-15
Recruiting
Therapeutic Efficacy and Safety Evaluation of AI in the Management of Diabetes: A RCT Trial
NCT06957093Diabetes Mellitus Type 2 (T2DM), Artificial Intelligence (AI)
The First Hospital of Jilin University
Not applicable
400
Changchun
2025-06-15
Not yet open
Changchun Intellicrown Pharmaceutical Co. LTD
Phase 1/2
40
Changchun
2025-06-10
Recruiting
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Guangzhou, Changsha, Changchun, Shanghai, Ürümqi, Hangzhou
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Recruiting
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun
2025-06-08
Recruiting
AstraZeneca
Phase 3
15,100
Anqing, Anyang, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha
2025-06-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
Recruiting
Yehui Tan
Phase 3
68
Changchun
2025-06-01
Active, closed
Second Hospital of Jilin University
Observational
2,000
Changchun
2025-06-01
Recruiting
Yehui Tan
Phase 2
70
Changchun
2025-06-01
Not yet open
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial
Peking University People's Hospital
Not applicable
1,389
Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao
2025-06
By invitation
Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
NCT06914661Breast Cancer Metastatic, Efficacy and Safety
The First Hospital of Jilin University
Observational
200
Changchun
2025-05-25
Recruiting
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
NCT06902350Neoplasms, Glioblastoma, Adult, Small Cell Lung Carcinoma (SCLC)
Chipscreen Biosciences, Ltd.
Phase 1
102
Beijing, Changchun
2025-05-21
Recruiting
The First Hospital of Jilin University
Observational
500
Changchun
2025-05-21
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian
2025-05-20
Recruiting
The First Hospital of Jilin University
Observational
500
Changchun
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai
2025-05-16
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
Baotou, Beijing, Changchun, Guangzhou, Harbin, Kaili, Linfen, Nanyang
2025-05-15
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai
2025-05-12
Recruiting
Takeda
Phase 2
88
Beijing, Guangzhou, Changchun, Shanghai
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Active, closed
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 2
30
Beijing, Zhengzhou, Nanchang, Changchun, Jinan, Luoyang, Taiyuan, Taizhou
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Recruiting
Yi Yang
Not applicable
178
Changchun
2025-04-25
Recruiting
BioNTech SE
Phase 1/2
380
Bengbu, Changchun, Chengdu, Chongqing, Huizhou, Nanning, Shanghai, Xi'an
2025-04-23
Active, closed
Zhejiang Doer Biologics Co., Ltd.
Phase 2
110
Hangzhou, Changchun, Nanjing
2025-04-22
By invitation
China-Japan Union Hospital
Not applicable
30
Changchun
2025-04-21
Recruiting
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
Epygenix
Phase 3
260
Changsha, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang
2025-04-09
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
16
Changchun
2025-04-08
Active, closed
Qilu Pharmaceutical Co., Ltd.
Phase 1
48
Changchun
2025-04-06
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
1,500
Guiyang, Changchun, Jinan, Shanghai, Jiaxing
2025-04-06
Recruiting
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Recruiting
AstraZeneca
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
700
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Anyang, Beijing, Changchun, Changzhou, Chengdu, Fuzhou, Hangzhou, Harbin
2025-03-27
Recruiting
Jianmin Pharmaceutical Group Co., LTD.
Phase 2
216
Harbin, Changsha, Changchun, Jinan, Luzhou, Tianjin, Wenzhou
2025-03-26
Recruiting
AstraZeneca
Phase 2
540
Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot
2025-03-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Beijing, Chongqing, Changsha, Changchun, Chengdu
2025-03-25
Recruiting
Daiichi Sankyo
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-03-19
Recruiting
AstraZeneca
Phase 3
990
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-03-17
Recruiting
AstraZeneca
Phase 3
11,300
Baotou, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng
2025-03-14
Recruiting
Bristol-Myers Squibb
Phase 3
60
Beijing, Chongqing, Guangzhou, Nanjing, Changchun, Hangzhou, Shanghai
2025-03-13
Recruiting
Shanghai Best-Link Bioscience, LLC
Phase 1
9
Changchun, Jinan
2025-03-10
Recruiting
The First Hospital of Jilin University
Phase 2
25
Changchun
2025-03-08
Recruiting
AstraZeneca
Phase 3
5,000
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongwan
2025-03-03
Active, closed
Songling Zhang
Early Phase 1
60
Changchun
2025-03-01
Not yet open
Ying Gao
Observational
4,460
Lanzhou, Harbin, Zhengzhou, Nanjing, Xuzhou, Changchun, Jining, Xian
2025-03-01
Recruiting
AstraZeneca
Phase 3
840
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou
2025-03-01
Recruiting
Children's Hospital of Soochow University
Not applicable
90
Wuhan, Suzhou, Changchun
2025-03
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
342
Beijing, Lanzhou, Guiyang, Shijiazhuang, Xingtai, Baoding, Luoyang, Changchun
2025-02-27
Recruiting
Daiichi Sankyo
Observational
260
Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2025-02-27
Recruiting
The First Hospital of Jilin University
Not applicable
2,250
Changchun
2025-02-25
Recruiting
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
DrugsAWT020·Taxol·Pemetrexed·Capecitabine
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
214
Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun
2025-02-21
Active, closed
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
Recruiting
Peking Union Medical College Hospital
Not applicable
524
Lanzhou, Guangzhou, Cangzhou, Shijiazhuang, Changsha, Changchun, Shanghai, Xianyang
2025-02-20
Recruiting
Jilin Heart Hospital
Phase 3
500
Changchun
2025-02-15
Active, closed
Genmab
Phase 3
584
Guangzhou, Xi'an, Changchun, Hanzhou, Shanghai, Tianjin, Zhengzhou
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Recruiting
The First Hospital of Jilin University
Observational
600
Changchun
2025-02-05
Recruiting
LEO Pharma
Phase 3
90
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen
2025-02-05
Recruiting
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Ha’erbin
2025-02-03
Active, closed
The First Hospital of Jilin University
Observational
200
Changchun
2025-02-01
Active, closed
Comparison of RIMA-SVG and Ao-SVG Techniques in Coronary Artery Bypass Grafting
NCT06787651Coronary Artery Bypass Grafting, Coronary Artery Disease, Saphenous Vein, Graft Patency
Second Hospital of Jilin University
Not applicable
300
Changchun
2025-02-01
Recruiting
Sinocelltech Ltd.
Phase 1/2
168
Beijing, Changchun, Guangzhou, Hangzhou, Jiujiang, Kunming, Linfen, Mianyang
2025-02
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Recruiting
The First Hospital of Jilin University
Phase 2
46
Changchun
2025-01-22
Recruiting
The First Hospital of Jilin University
Not applicable
40
Changchun
2025-01-17
Active, closed
Janssen Research & Development, LLC
Phase 3
813
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guiyang
2025-01-09
Recruiting
BioNTech SE
Phase 2/3
1,580
Baoding, Beijing, Bengbu, Changchun, Changsha, Hangzhou, Jiamusi, Jinan
2025-01-07
Active, closed
Amgen
Phase 2
61
Beijing, Fuzhou, Zhengzhou, Wuhan, Changsha, Changchun, Jinan, Shanghai
2024-12-26
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Active, closed
AstraZeneca
Phase 2/3
432
Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu
2024-12-06
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Recruiting
Jilin University
Not applicable
60
Changchun
2024-12-04
Recruiting
Retroperitoneal Tumor Registry
NCT07915895Retroperitoneal Neoplasms
The First Hospital of Jilin University
Observational
200
Changchun
2024-12-01
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Recruiting
The First Hospital of Jilin University
Observational
90
Changchun
2024-11-25
Recruiting
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation
DrugsABSK043·Furmonertinib
Abbisko Therapeutics Co, Ltd
Phase 2
54
Hefei, Harbin, Wuhan, Changchun, Shanghai
2024-11-25
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Recruiting
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Recruiting
The First Hospital of Jilin University
Observational
300
Changchun
2024-11-20
Active, closed
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Active, closed
Biotheus Inc.
Phase 3
404
Binzhou, Changchun, Changsha, Chengdu, Chenzhou, Chongqing, Dalian, Foshan
2024-11-13
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-11-12
Active, closed
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
Recruiting
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
NCT07439991Lung Cancer (Diagnosis), Deep Vein Thrombosis (DVT), Venous Thromboembolism (VTE)
The First Hospital of Jilin University
Observational
900
Changchun
2024-11-01
Not yet open
Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging
NCT06681155Coronary Arterial Disease (CAD), Acute Coronary Syndromes
Chinese PLA General Hospital
Observational
500
Shenzhen, Wuhan, Changchun, Xi'an, Ürümqi, Hangzhou, Beijing
2024-11
Not yet open
A Prospective Cohort of Patients With Cervical/Intracranial Arteries Stenosis in China
NCT06595342Cervical Artery Stenosis, Intracranial Artery Stenosis
The First Hospital of Jilin University
Observational
60,000
Changchun
2024-10-30
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
432
Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou
2024-10-30
Not yet open
Yi Yang
Phase 4
1,200
Changchun
2024-10-30
Active, closed
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Recruiting
Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
NCT07119463Postoperative Hypoalbuminemia, Postoperative Complications, Gastric Cancer
The First Hospital of Jilin University
Phase 2
112
Changchun
2024-10-29
Active, closed
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-10-14
Recruiting
Amgen
Phase 1
220
Changchun, Shanghai
2024-10-07
Active, closed
AstraZeneca
Phase 3
768
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Deyang, Ganzhou
2024-10-04
By invitation
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
Active, closed
AstraZeneca
Phase 3
293
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Dalian, Deyang
2024-09-26
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Active, closed
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Recruiting
Doppler Ultrasound-Guided Angiopuncture for Dysmenorrhea Pain: A Clinical Trial
NCT07176910Angiopuncture, Dysmenorrhea, Dopplar Ultrasound
City University of Hong Kong
Not applicable
30
Changchun
2024-09-01
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Active, closed
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Active, closed
AstraZeneca
Phase 4
731
Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin
2024-08-23
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Shanghai, Changchun, Beijing
2024-08-15
Recruiting
Hypofractionated Radiotherapy
NCT06740955Glioblastoma
The First Hospital of Jilin University
Not applicable
420
Changchun
2024-08-13
Recruiting
The First Hospital of Jilin University
Phase 1/2
35
Changchun
2024-08-13
Recruiting
AstraZeneca
Phase 3
620
Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou
2024-08-12
Active, closed
Pfizer
Observational
450
Beijing, Changchun, Changsha, Guangzhou, Shanghai
2024-08-07
Recruiting
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Recruiting
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
216
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanning, Nantong, Qingdao
2024-07-30
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Hefei, Beijing, Lanzhou, Harbin, Changsha, Changchun, Jinan, Chengdu
2024-07-19
Recruiting
Harbin Medical University
Observational
350
Harbin, Changchun
2024-07-07
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Recruiting
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
90
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jinan, Kunming
2024-06-30
Active, closed
The First Hospital of Jilin University
Phase 2
35
Changchun
2024-06-30
Active, closed
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
2024-06-28
Recruiting
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Dalian
2024-06-17
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Recruiting
InnoCare Pharma Inc.
Phase 3
476
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2024-05-29
Active, closed
Amgen
Phase 1
120
Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun
2024-05-29
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Recruiting
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
Recruiting
IDEAL Study: Blinded RCT for the Impact of AI Model for Cerebral Aneurysms Detection on Patients' Diagnosis and Outcomes
NCT06118840Intracranial Aneurysm, CT Angiography, Deep Learning, Double Bind Interaction
Jinling Hospital, China
Not applicable
6,450
Hefei, Wuhu, Guiyang, Zhengzhou, Shiyan, Nanjing, Xuzhou, Changchun
2024-05-20
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
244
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-05-07
Recruiting
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)
NCT06539182Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugBirelentinib
Dizal Pharmaceuticals
Phase 2
155
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun, Dalian
2024-04-29
Recruiting
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
The First Hospital of Jilin University
Not applicable
1,084
Changchun
2024-04-29
Active, closed
Evolve China PMCF Study
NCT06368622Intracranial Aneurysm
Stryker Neurovascular
Observational
500
Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao
2024-04-24
Active, closed
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot
2024-04-16
Active, closed
argenx
Phase 3
119
Beijing, Changchun, Chongqing, Fuzhou, Guangxi, Guangzhou, Guiyang, Ningbo
2024-04-16
Recruiting
AstraZeneca
Phase 3
3,850
Baotou, Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Guangzhou
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Active, closed
AstraZeneca
Phase 3
2,554
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2024-03-29
Active, closed
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
260
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Not yet open
Yi Yang
Not applicable
986
Changchun
2024-03-15
Recruiting
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Active, closed
Eli Lilly and Company
Phase 3
17,300
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng, Chongqing
2024-03-05
Active, closed
AstraZeneca
Phase 3
594
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-03-04
Active, closed
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Active, closed
Novartis Pharmaceuticals
Phase 3
1,466
Beijing, Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Changchun, Jinan
2024-02-28
Active, closed
AstraZeneca
Phase 2
127
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongyang, Guangzhou, Hangzhou
2024-02-22
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
42
Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan
2024-01-26
Active, closed
Sanofi
Phase 3
260
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2024-01-23
Recruiting
Tongji Hospital
Observational
250
Wuhan, Beijing, Changchun, Chongqing, Nanjing
2024-01-20
Recruiting
Daiichi Sankyo
Phase 3
75
Changchun, Harbin, Hefei
2024-01-05
Recruiting
The First Hospital of Jilin University
Observational
40
Changchun
2024-01-01
Active, closed
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Active, closed
Sanofi
Phase 3
943
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Jiazhuang
2023-12-27
Recruiting
Eli Lilly and Company
Phase 3
1,264
Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou
2023-12-21
Recruiting
AstraZeneca
Phase 3
1,145
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou
2023-12-14
Active, closed
Sanofi
Phase 3
1,655
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou
2023-12-13
Active, closed
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, Ürümqi
2023-12-07
Recruiting
Changchun Intellicrown Pharmaceutical Co. LTD
Phase 1
138
Changchun
2023-12-06
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Deyang, Fuzhou, Guangzhou, Guiyang
2023-12-04
Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
Recruiting
Yi Yang
Not applicable
500
Changchun
2023-11-25
Recruiting
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Active, closed
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
100
Changchun
2023-11-10
Recruiting
LeonaBio
Phase 3
600
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun
2023-10-31
Recruiting
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
NCT06247605Small Cell Lung Carcinoma
DrugAL8326
Advenchen Laboratories Nanjing Ltd.
Phase 3
243
Changchun
2023-10-26
Active, closed
AstraZeneca
Phase 3
895
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-10-24
Recruiting
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
180
Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan
2023-10-19
Recruiting
AbbVie
Phase 3
1,500
Beijing, Chongqing, Guangzhou, Shenzhen, Wuhan, Nanchang, Changchun, Xi'an
2023-10-11
Active, closed
AstraZeneca
Phase 3
5,511
Baoding, Beijing, Bengbu, Binzhou, Cangzhou, Changchun, Changsha, Chengdu
2023-10-05
Recruiting
Recurrent High Grade Glioma Treated by LITT
NCT06161610Recurrent High Grade Glioma
Beijing Tiantan Hospital
Not applicable
135
Beijing, Guangzhou, Zhengzhou, Wuhan, Changchun, Shenyang, Jinan, Shanghai
2023-09-19
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangdong Province Guangzhou City, Guangzhou
2023-09-18
Recruiting
RemeGen Co., Ltd.
Phase 1/2
221
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2023-09-14
Active, closed
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai
2023-09-13
Recruiting
Hoffmann-La Roche
Phase 3
230
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan
2023-09-08
Recruiting
Gilead Sciences
Phase 3
402
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei
2023-09-07
Not yet open
The First Hospital of Jilin University
Phase 2
45
Changchun
2023-09-01
Active, closed
Janssen Research & Development, LLC
Phase 3
420
Beijing, Changchun, Chengdu, Guangzhou, Jinan, Ningbo, Shenyang, Wuhan
2023-08-31
Active, closed
Hoffmann-La Roche
Observational
1,000
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Haikou, Hohhot
2023-08-25
Recruiting
AstraZeneca
Phase 3
231
Beijing, Changchun, Hohhot, Lanzhou, Nanjing, Shanghai, Shenyang, Shenzhen
2023-08-24
Recruiting
Shouchun Wang, MD, PhD
Observational
416
Changchun
2023-08-23
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
DrugDS-3939a
Daiichi Sankyo
Phase 1/2
590
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Nanchang, Neijiang
2023-08-18
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Active, closed
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
NCT05896124Primary Biliary Cholangitis (PBC)
DrugPleacbo
Cascade Pharmaceuticals, Inc
Phase 2
75
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Zhenjiang, Changchun
2023-08-07
Recruiting
GlaxoSmithKline
Phase 3
892
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2023-08-01
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
DrugFutibatinib
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Active, closed
Peking University Hospital of Stomatology
Phase 2
110
Beijing, Baoding, Tangshan, Harbin, Chifeng, Hohhot, Changchun, Shenyang
2023-06-27
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
169
Chongqing, Luoyang, Zhengzhou, Wuhan, Changsha, Hohhot, Nanchang, Changchun
2023-06-26
Recruiting
FengYan Jin
Observational
50
Changchun
2023-06-15
Recruiting
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
NCT05774288Patent Foramen Ovale, Cryptogenic Stroke
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
244
Beijing, Guangzhou, Meizhou, Changsha, Changchun, Shenyang, Jinan, Kunming
2023-06-08
Recruiting
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Recruiting
Yi Yang
Observational
3,000
Changchun
2023-06-05
Recruiting
Hoffmann-La Roche
Phase 3
200
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Active, closed
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Recruiting
Peking Union Medical College Hospital
Not applicable
2,478
Beijing, Changchun, Changsha, Changzhou, Chengdu, Dalian, Dongying, Guiyang
2023-05-26
Recruiting
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
200
Luoyang, Wuhan, Nanjing, Nanchang, Changchun, Dalian, Baotou, Kunming
2023-05-11
Active, closed
Gilead Sciences
Phase 3
654
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou
2023-05-08
Recruiting
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
NCT05892042ST-segment Elevation Myocardial Infarction (STEMI), Left Ventricular Thrombus
DrugRivaroxaban
Jilin University
Not applicable
320
Changchun
2023-05-01
Recruiting
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
374
Fuzhou, Guangzhou, Guiyang, Anyang, Luoyang, Pingxiang, Changchun, Yinchuan
2023-04-24
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Active, closed
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Recruiting
AstraZeneca
Phase 3
4,300
Baoding, Beijing, Changchun, Changsha, Chengdu, Chifeng, Dalian, Foshan
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Recruiting
F573 for Injection for the Treatment of Liver Injury/Failure
NCT05689645Acute Liver Failure, Acute-On-Chronic Liver Failure
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2
97
Beijing, Qingyuan, Shiyan, Huaihua, Pingxiang, Changchun, Binzhou, Heze
2023-03-24
Active, closed
SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Changchun, Tianjin
2023-02-28
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
146
Guangzhou, Changchun, Chengdu
2023-02-23
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Anyang, Baoji, Baotou, Beijing, Changchun, Changsha, Chengdu, Chenzhou
2023-02-15
Active, closed
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Active, closed
Klus Pharma Inc.
Phase 2
240
Guangzhou, Nanning, Wuhan, Changsha, Changchun, Dalian, Weifang, Xi’an
2023-01-17
Active, closed
Daiichi Sankyo
Phase 3
1,170
Beijing, Beijing Sheng, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-01-11
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Beijing, Lanzhou, Guangzhou, Shantou, Nanning, Shijiazhuang, Wuhan, Changchun
2022-12-27
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Heping, Nanchang
2022-12-23
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Fuzhou, Changsha, Changchun, Hangzhou, Taizhou
2022-12-20
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Beijing, Changchun, Jinan
2022-12-20
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Active, closed
Janssen Research & Development, LLC
Phase 3
214
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Recruiting
AstraZeneca
Phase 3
3,527
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou
2022-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Recruiting
FengYan Jin
Not applicable
41
Changchun
2022-12-02
Recruiting
Xuanwu Hospital, Beijing
Observational
16,000
Beijing, Changchun, Chengdu, Suzhou
2022-12-01
Active, closed
AstraZeneca
Phase 3
1,174
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2022-11-28
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Jinan, Qingdao
2022-11-21
Recruiting
C2 Esophageal Squamous Epithelium Dysplasia
NCT05349240Esophageal Squamous Epithelium Dysplasia
Pentax Medical
Not applicable
129
Beijing, Changchun, Changzhi, Shijiazhuang
2022-11-18
Recruiting
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1/2
100
Changchun
2022-11-18
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Recruiting
Pfizer
Phase 3
1,060
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou
2022-10-25
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Beijing, Changchun, Changsha, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2022-10-13
Active, closed
Bayer
Phase 1
129
Guangzhou, Changchun, Linyi
2022-10-11
Active, closed
Eli Lilly and Company
Phase 3
15,374
Beijing, Changchun, Changping, Chengdu, Chongqing, Haikou, Harbin, Hengshui Shi
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou Fujian, Guangzhou, Haidian District
2022-10-10
Active, closed
Genmab
Phase 3
72
Baoding, Beijing, Changchun, Chengdu, Dalian, Guandong, Guangxi, Hangzhou
2022-10-08
Active, closed
Eli Lilly and Company
Phase 3
8,000
Anyang, Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang
2022-10-04
Active, closed
Allist Pharmaceuticals, Inc.
Phase 2
100
Changchun
2022-09-27
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan
2022-09-23
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
381
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Recruiting
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
344
Quanzhou, Guangzhou, Shantou, Ganzhou, Changsha, Hengyang, Changchun, Shenyang
2022-09-01
Active, closed
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing
2022-08-30
Active, closed
Novo Nordisk A/S
Phase 3
412
Beijing, Guangzhou, Liuzhou, Sanya, Zhengzhou, Wuhan, Changsha, Changchun
2022-08-10
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Active, closed
AstraZeneca
Phase 3
341
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2022-08-03
Recruiting
China HEalthy Aging and Dementia Study (HEAD)
NCT07912710Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD)
Fudan University
Observational
20,000
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan
2022-08-01
Active, closed
Hoffmann-La Roche
Phase 3
922
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou
2022-07-18
Active, closed
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Active, closed
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Active, closed
Daiichi Sankyo
Phase 3
586
Beijing, Changchun, Changsha, Chengdu, Chibi, Fuzhou, Guangzhou, Haidian
2022-07-08
Active, closed
Pfizer
Phase 2
35
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun, Shenyang
2022-07-07
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Recruiting
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
180
Changchun
2022-07-07
Active, closed
Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)
NCT05382364Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
DrugTucatinib
Pfizer
Phase 1
25
Harbin, Changsha, Changchun, Shanghai, Tianjin
2022-06-29
Active, closed
Celgene
Phase 3
939
Changsha, Nanchang, Xi'an, Shanghai, Taiyuan, Wenzhou, Beijing, Changchun
2022-06-23
Active, closed
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Active, closed
Biotheus Inc.
Phase 2
99
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Harbin, Jinan, Nanchang
2022-05-27
Active, closed
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
DrugLorlatinib
CStone Pharmaceuticals
Phase 2
70
Guangzhou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2022-05-27
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
82
Bengbu, Guangzhou, Guilin, Wuhan, Yueyang, Changchun, Hangzhou
2022-05-20
Active, closed
AstraZeneca
Phase 3
644
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-05-16
Recruiting
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Active, closed
Pfizer
Phase 1/2
235
Changchun, Shanghai, Chengdu, Tianjin, Hangzhou
2022-03-14
Active, closed
Daiichi Sankyo
Phase 2
187
Changchun, Changsha, Chengdu, Guangdong, Hangzhou, Linyi, Shanghai, Wuhan
2022-03-09
Active, closed
Daiichi Sankyo
Phase 3
740
Nanning, Zhengzhou, Changchun, Chengdu, Beijing, Cangzhou, Changsha, Chongqing
2022-03-04
Active, closed
AstraZeneca
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-02-21
Active, closed
AstraZeneca
Phase 3
1,051
Anyang, Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Hefei, Kunming
2022-02-07
Rows per page Showing 1–500 of 640
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/changchun

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 640 of those studies with a site in Changchun.

How many clinical trials are recruiting in Changchun?

335 of the 640 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 58 have not yet opened recruitment, 236 are active but closed to new participants, and 11 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changchun), 640 studies
PhaseStudiesRecruitingShare
Phase 329514246.1%
Phase 21035116.1%
Not applicable664410.3%
Observational57318.9%
Phase 147257.3%
Phase 1/236255.6%
Phase 41872.8%
Phase 2/316102.5%
Early Phase 1200.3%

Most active sponsors

Lead sponsors with the most studies (Changchun)
Lead sponsorStudiesRecruiting
AstraZeneca10549
The First Hospital of Jilin University4934
Hoffmann-La Roche3113
Janssen Research & Development, LLC3010
Eli Lilly and Company2512
Novartis Pharmaceuticals218
Daiichi Sankyo1810
Boehringer Ingelheim1514
Sanofi123
Pfizer114
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.